Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track XENE with free AI briefings, catalyst countdowns, and dilution alerts.

XENE · Xenon Pharmaceuticals Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.2B Cash on Hand
37.3mo Cash Runway
Follow XENE by email Get an email when XENE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about XENE, unsubscribe in one click. Privacy

📣 What XENE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Azetukalner (XEN1101) Bipolar Depression Phase 3 · NCT07217860 Active not recruiting
Ezogabine Epilepsy Phase 3 · NCT04912856 Terminated
XPF-001 Dental Pain Phase 2 · NCT00954356 Completed
XPF-002 Primary Erythromelalgia Phase 1/2 · NCT01486446 Completed
XPF-005 Acne Vulgaris Phase 1/2 · NCT02656043 Completed
14C-XEN1101 Healthy Volunteers Phase 1 · NCT04952467 Completed
Inert Ingredients Oral Product Healthy Volunteers Phase 1 · NCT03467100 Completed
Cellulose, Microcrystalline Healthy Volunteers Phase 1 · NCT03340220 Completed
XEN901 Healthy Volunteers Phase 1 · NCT03467100 Completed
XPF-008 Healthy Volunteers Phase 1 · NCT03340220 Completed
XPF-010 Healthy Volunteers Phase 1 · NCT03340220 Completed

Also used in these trials (approved or third-party drugs, not XENE's own candidates): Itraconazole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

XENE holds $1.2B in cash and short-term investments (as of Sep 30, 2026) and burns about $92.9M/quarter from operations, an estimated runway of 37.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 39 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when XENE files for a raise →

👥 Who Owns XENE

Insiders 0.2% Institutions (435 holders) 99.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 11,136,649 11.33% 2026-09-30
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 9,996,124 10.17% 2026-10-31
Avoro Capital Advisors LLC Institution (13G, 5%+) 5,777,777 5.88% 2026-03-31
Ian Mortimer
PRESIDENT & CEO, Director · +452,500 options
Insider 64,223 0.07% 2026-09-30
Dawn Svoronos
Director · +12,100 options
Insider 31,373 0.03% 2026-09-01
Gary Patou
Director · +29,112 options
Insider 29,798 0.03% 2026-06-05
Thomas Patrick Kelly
Chief Financial Officer · +277,500 options
Insider 22,500 0.02% 2026-10-15
Andrea DiFabio
Chief Legal Officer · +106,250 options
Insider 7,301 0.01% 2026-03-12
Elizabeth A. Garofalo
Director · +29,112 options
Insider 2,645 0.00% 2026-06-01
Justin D. Gover
Director · +29,112 options
Insider 2,645 0.00% 2026-06-01
Patrick Machado
Director · +29,112 options
Insider 2,645 0.00% 2026-06-01
Steven Gannon
Director · +29,112 options
Insider 1,870 0.00% 2026-08-11

Share count 98,284,734 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full XENE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XENE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.